kabutan

PhoenixBio Co.,Ltd.(6190) Summary

6190
TSE Growth
PhoenixBio Co.,Ltd.
550
JPY
-12
(-2.14%)
Dec 5, 11:27 am JST
3.54
USD
Dec 4, 9:27 pm EST
Result
PTS
outside of trading hours
551.1
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
20.3
PBR
1.64
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
560 JPY 3.60 USD
Previous Close Dec 4
562 JPY 3.61 USD
High Dec 5, 9:44 am
596 JPY 3.84 USD
Low Dec 5, 9:04 am
530 JPY 3.41 USD
Volume
503,200
Trading Value
0.28B JPY 1.83M USD
VWAP
565.03 JPY 3.64 USD
Minimum Trading Value
55,000 JPY 354 USD
Market Cap
2.24B JPY 0.01B USD
Number of Trades
1,715
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
343
1-Year High Feb 25, 2025
13,787
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 272,700
Nov 21, 2025 0 264,300
Nov 14, 2025 0 349,400
Nov 7, 2025 0 367,700
Oct 31, 2025 0 332,100
Company Profile
PhoenixBio Co., Ltd. is a biotech venture originating from Hiroshima University, specializing in the production of PXB mice with high human hepatocyte replacement rates and contract testing services.
Sector
Services
PhoenixBio, a biotech venture spun off from Hiroshima University, primarily focuses on providing contract testing services for drug development using PXB mice. PXB mice are chimeric mice with livers largely replaced by human hepatocytes, used for predicting human metabolism and researching hepatitis viruses. The company's main services include pharmacokinetic studies, safety tests, and efficacy evaluations for hepatitis drugs. Additionally, PhoenixBio sells fresh human hepatocytes (PXB-cells) obtained from PXB mice. These services play a crucial role in the preclinical stages of new drug development, supporting pharmaceutical companies in their drug discovery research.